Deep Brain Stimulation (DBS), also known as a "brain pacemaker," is a revolutionary, technology-driven treatment system used in neurological and psychiatric disorders. Electrodes are surgically implanted in specific areas of the brain and connected to a subcutaneously implanted pulse generator in the chest. This system delivers controlled electrical impulses to targeted brain circuits to help correct disease-related dysfunctions.
Parkinson’s Disease: Effectively reduces tremors, rigidity, and bradykinesia (slowness of movement).
Essential Tremor: Significantly alleviates tremor symptoms.
Dystonia: Especially effective when targeting the globus pallidus internus (GPi) to improve muscle control.
Epilepsy: Used in drug-resistant cases, particularly with anterior thalamic nucleus stimulation.
Obsessive-Compulsive Disorder (OCD): Received Humanitarian Device Exemption (HDE) approval by the FDA in 2009.
Research is ongoing in promising areas such as depression, chronic pain, weight control, and addiction.
Motor Symptom Improvement (40–60% or more): Marked improvement in patients with Parkinson’s and tremor.
Reduced Medication Dependency: Particularly in Parkinson’s disease, DBS may significantly reduce the need for medication.
Adaptive Stimulation: New-generation adaptive DBS (aDBS) systems operate based on real-time brain signals, minimizing side effects.
Reversibility: The system can be adjusted or deactivated externally as needed, providing a flexible treatment option.
Implantation Stages: Electrodes are implanted into the brain, and the pulse generator is placed under the skin in the chest.
Surgical Risks: Include bleeding, infection, and intracranial complications.
Possible Side Effects: Temporary headache, numbness, speech disturbances, or mood changes may occur.
Adaptive DBS (aDBS): Adjusts stimulation based on brain activity for personalized therapy. FDA-approved Medtronic BrainSense systems are now in clinical use in the U.S.
Depression Treatment: Implantation targeting the subcallosal cingulate region has shown up to 60% success, and FDA reviews in this area are accelerating.
